Threshold Pharmaceuticals Inc

Type: Company
Name: Threshold Pharmaceuticals Inc
Nationality: United States
Web Address: http://www.thresholdpharm.com/
First reported Apr 15 2014 - Updated Apr 15 2014 - 2 reports

Shares of Threshold Pharmaceuticals Fall Below Previous 52-Week Low

Shares of Threshold Pharmaceuticals (NASDAQ:THLD) traded at a new 52-week low today of $3.80. Approximately 690,000 shares have changed hands today, as compared to an average 30-day volume of 624,000 shares. ... [Published Individual.com - Apr 15 2014]
First reported Apr 14 2014 - Updated Apr 14 2014 - 1 reports

IPOs and Transactions: April 7 - 11

SOURCE PR Newswire Association LLCLast week's review of corporations, SEC form type and law firmsNEW YORKHighlighted corporations and law firms include: Registrant Symbol Form Law firm / advisor LAREDO GAS SERVICES, LLC S-4 Akin Gump Strauss Hauer & Feld ... [Published WLNS - Apr 14 2014]
First reported Apr 10 2014 - Updated Apr 11 2014 - 1 reports

Possible Bearish Inside Day Candle Pattern Detected for Threshold Pharmaceuticals (NASDAQ:THLD)

Written on Thu, 04/10/2014 - 3:30pmBy Nick RussoSmarTrend's candlestick scanner has spotted a possible bearish inside day candle pattern in Threshold Pharmaceuticals ( NASDAQ:THLD ) based on the price action in the company's shares. Today's price range ... [Published Comtex SmarTrend - Apr 10 2014]
First reported Apr 03 2014 - Updated Apr 03 2014 - 1 reports

Threshold Pharmaceuticals Announces Results of Two New Preclinical Studies Evaluating Novel Combinations of TH-302 With Immunotherapy, Antiangiogenic Therapy, and Radiotherapy to Be Presented at AACR Annual Meeting 2014

SOUTH SAN FRANCISCO, CA--(Marketwired - Apr 3, 2014) - Threshold Pharmaceuticals, Inc. (NASDAQ: THLD) today announced that results of two new preclinical studies evaluating novel combinations of TH-302, its investigational hypoxia-targeted drug, with ... [Published Marketwire - Breaking News Releases - Apr 03 2014]
First reported Apr 02 2014 - Updated Apr 02 2014 - 1 reports

Merck initiates Phase I pancreatic adenocarcinoma study

Threshold Pharmaceuticals, Inc., a biotechnology company, has announced that its partner Merck KGaA has initiated a Phase I dose escalation study assessing the safety, tolerability and anti-tumor activity of the investigational hypoxia-targeted drug TH-302 ... [Published Individual.com - Apr 02 2014]
First reported Apr 01 2014 - Updated Apr 02 2014 - 2 reports

Global pancreatic cancer market to treble in value

The global pancreatic cancer market is experiencing rapid expansion and is set to hit $1.6bn by 2017, largely driven by strong performance from Celgene's Abraxane. It's a strong validation for Abraxane, which has only recently been approved for pancreatic ... [Published PMLive - Apr 02 2014]
First reported Apr 01 2014 - Updated Apr 01 2014 - 1 reports

Global Pancreatic Cancer Treatment Market Value To More Than Treble By 2017, Says

- The global pancreatic cancer treatment market value in the six major countries (6MM: the US, France, Germany, Italy, Spain and the UK) will increase significantly from $529 million in 2012 to $1.63 billion by 2017, at an impressive Compound Annual Growth ... [Published BioSpace - Apr 01 2014]
First reported Mar 31 2014 - Updated Mar 31 2014 - 1 reports

Biotechs Are Crashing: Here's This Week's Action Plan

If you hold any biotech stocks in your portfolio, then it's time for a gut check.Share prices in this high-risk/high-reward group posted their biggest one-week loss in recent memory, leading investors to figure out if it's time to get out now... or to ... [Published StreetAuthority - Mar 31 2014]
First reported Mar 27 2014 - Updated Mar 27 2014 - 1 reports

Threshold Pharmaceuticals' Partner Merck KGaA, Darmstadt, Germany Initiates Phase 1 Dose Escalation Study of TH-302 in Combination With Gemcitabine and Nab-paclitaxel (Abraxane(R)) in Pancreatic Cancer

SOUTH SAN FRANCISCO, CA--(Marketwired - Mar 27, 2014) - Threshold Pharmaceuticals, Inc. (NASDAQ: THLD) today announced that Threshold's partner Merck KGaA, Darmstadt, Germany, through its biopharmaceutical division, has initiated a Phase 1 dose escalation ... [Published Marketwire - Breaking News Releases - Mar 27 2014]
First reported Mar 26 2014 - Updated Mar 26 2014 - 1 reports

THRESHOLD PHARMACEUTICALS : Patent Application Titled "Unit Dose Form for Oral Administration" Published Online

By a News Reporter-Staff News Editor at Biotech Week -- According to news reporting originating from Washington, D.C. , by NewsRx journalists, a patent application by the inventors Jung, Donald ( South San Francisco, CA ); Matteucci, Mark ( South San ... [Published 4 Traders - Mar 26 2014]
First reported Mar 25 2014 - Updated Mar 26 2014 - 1 reports

Frontline Ltd.(NYSE:FRO), Threshold Pharmaceuticals, Inc.(NASDAQ:THLD), Cincinnati Bell Inc.(NYSE:CBB), Forest Oil Corporation(NYSE:FST)

Frontline Ltd. (FRO) engaged in the possession and operation of oil tankers and oil/bulk/ore carriers. The company provides seaborne transportation of crude oil and oil products, as well as raw materials, such as coal and iron ore.Frontline Ltd. (NYSE:FRO) ... [Published 4 Traders - Mar 25 2014]
First reported Mar 06 2014 - Updated Mar 06 2014 - 2 reports

Threshold Pharmaceuticals Reports Fourth Quarter and Year End 2013 Financial and Operational Results

"We began 2014 with the first pivotal trial of TH-302 in advanced soft tissue sarcoma fully enrolled, the second pivotal trial in advanced pancreatic cancer being conducted by our partner Merck KGaA well underway, and a third registration program in another ... [Published Stockwatch - Mar 06 2014]

Quotes

...is an important component of the overall development program for TH-302 in pancreatic cancer," said Barry Selick, Ph D , CEO of Threshold. "We are pleased that Merck in Darmstadt, Germany has initiated this additional trial designed to evaluate an investigational triplet therapeutic regimen for patients with pancreatic cancer while continuing to enroll the Phase III MAESTRO study."

More Content

All (24) | News (20) | Reports (0) | Blogs (4) | Audio/Video (0) | Fact Sheets (0) | Press Releases (0)
sort by: Date | Relevance
Acute Myelocytic Leukemia (AML, Acute Myeloblas... [Published SBWire - Apr 16 2014]
Shares of Threshold Pharmaceuticals Fall Below ... [Published Individual.com - Apr 15 2014]
Threshold Pharmaceuticals: New 52-Week Low Set ... [Published Comtex SmarTrend - Apr 15 2014]
IPOs and Transactions: April 7 - 11 [Published WLNS - Apr 14 2014]
New Report Available: Acute Lymphocytic Leukemi... [Published SBWire - Apr 11 2014]
Possible Bearish Inside Day Candle Pattern Dete... [Published Comtex SmarTrend - Apr 10 2014]
Global Neuroendocrine Cancer Clinical Trials Re... [Published Individual.com - Apr 09 2014]
Pharma Opportunity/Analyzer Report: Pancreatic ... [Published Individual.com - Apr 07 2014]
Neuroendocrine Cancer Global Clinical Trials Re... [Published BioPortfolio - Apr 07 2014]
Threshold Pharmaceuticals Announces Results of ... [Published Marketwire - Breaking News Releases - Apr 03 2014]
Merck initiates Phase I pancreatic adenocarcino... [Published Individual.com - Apr 02 2014]
Global pancreatic cancer market to treble in value [Published PMLive - Apr 02 2014]
Global Pancreatic Cancer Treatment Market Value... [Published BioSpace - Apr 01 2014]
Pancreatic cancer drug market in 6 major market... [Published Pharma Letter - Apr 01 2014]
Biotechs Are Crashing: Here's This Week's Actio... [Published StreetAuthority - Mar 31 2014]
Threshold Pharmaceuticals' Partner Merck KGaA, ... [Published Marketwire - Breaking News Releases - Mar 27 2014]
THRESHOLD PHARMACEUTICALS : Patent Application ... [Published 4 Traders - Mar 26 2014]
Frontline Ltd.(NYSE:FRO), Threshold Pharmaceuti... [Published 4 Traders - Mar 25 2014]
3 Biotechnology Stocks Poised For Future Growth [Published Seeking Alpha - Mar 16 2014]
IsoRay: A $0.80 Stock That Should Be Trading At... [Published Seeking Alpha - Mar 14 2014]
Threshold Pharmaceuticals Reports Fourth Quarte... [Published Stockwatch - Mar 06 2014]
Threshold Pharmaceuticals Reports Fourth Quarte... [Published Marketwire - Breaking News Releases - Mar 06 2014]
Threshold Pharmaceuticals Announces Presentatio... [Published Marketwire - Breaking News Releases - Feb 20 2014]
Pancreatic Cancer Disease and Pipeline Analysis [Published BioPortfolio - Jan 29 2014]
1
In Focus
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
Content Volume
Document Volume
Network
Network

Blogs

sort by: Date | Relevance
Threshold Pharmaceuticals Announces Results of ... [Published Marketwire - Breaking News Releases - Apr 03 2014]
SOUTH SAN FRANCISCO, CA--(Marketwired - Apr 3, 2014) - Threshold Pharmaceuticals, Inc. (NASDAQ: THLD) today announced that results of two new preclinical studies evaluating novel combinations of TH-302, its investigational hypoxia-targeted drug, with ...
Threshold Pharmaceuticals' Partner Merck KGaA, ... [Published Marketwire - Breaking News Releases - Mar 27 2014]
SOUTH SAN FRANCISCO, CA--(Marketwired - Mar 27, 2014) - Threshold Pharmaceuticals, Inc. (NASDAQ: THLD) today announced that Threshold's partner Merck KGaA, Darmstadt, Germany, through its biopharmaceutical division, has initiated a Phase 1 dose escalation ...
Threshold Pharmaceuticals Reports Fourth Quarte... [Published Marketwire - Breaking News Releases - Mar 06 2014]
SOUTH SAN FRANCISCO, CA--(Marketwired - Mar 6, 2014) - Threshold Pharmaceuticals, Inc. (NASDAQ: THLD), today reported financial results for the fourth quarter and year ended December 31, 2013 and reported on clinical development objectives for TH-302, ...
Threshold Pharmaceuticals Announces Presentatio... [Published Marketwire - Breaking News Releases - Feb 20 2014]
SOUTH SAN FRANCISCO, CA--(Marketwired - Feb 20, 2014) - Threshold Pharmaceuticals, Inc. (NASDAQ: THLD) today announced that Barry Selick, Ph.D., Threshold's Chief Executive Officer, will present a company overview at three upcoming investor conferences: ...
1
Contact Us
Sales
Support


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2014 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.